Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Radiopharmaceuticals Market

ID: MRFR/HC/1119-CR
200 Pages
Nidhi Mandole
Last Updated: April 17, 2026

Radiopharmaceuticals Market Research Report: Size, Share, Trend Analysis By Applications (Diagnosis, Therapy, Research), By Types (Diagnostic Radiopharmaceuticals, Therapeutic Radiopharmaceuticals), By Radiopharmaceutical Class (Radioisotopes, Radiolabeled Compounds, Radiopharmaceutical Generators), By End Use (Hospitals, Diagnostic Imaging Centers, Research Institutions) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Radio Pharmaceutical Market Infographic
Purchase Options
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Healthcare, BY Application (USD Billion) | |
      1. 4.1.1 Diagnosis | |
      2. 4.1.2 Therapy | |
      3. 4.1.3 Research |
    2. 4.2 Healthcare, BY Type (USD Billion) | |
      1. 4.2.1 Diagnostic Radiopharmaceuticals | |
      2. 4.2.2 Therapeutic Radiopharmaceuticals |
    3. 4.3 Healthcare, BY Radiopharmaceutical Class (USD Billion) | |
      1. 4.3.1 Radioisotopes | |
      2. 4.3.2 Radiolabeled Compounds | |
      3. 4.3.3 Radiopharmaceutical Generators |
    4. 4.4 Healthcare, BY End Use (USD Billion) | |
      1. 4.4.1 Hospitals | |
      2. 4.4.2 Diagnostic Imaging Centers | |
      3. 4.4.3 Research Institutions |
    5. 4.5 Healthcare, BY Region (USD Billion) | |
      1. 4.5.1 North America | | |
        1. 4.5.1.1 US | | |
        2. 4.5.1.2 Canada | |
      2. 4.5.2 Europe | | |
        1. 4.5.2.1 Germany | | |
        2. 4.5.2.2 UK | | |
        3. 4.5.2.3 France | | |
        4. 4.5.2.4 Russia | | |
        5. 4.5.2.5 Italy | | |
        6. 4.5.2.6 Spain | | |
        7. 4.5.2.7 Rest of Europe | |
      3. 4.5.3 APAC | | |
        1. 4.5.3.1 China | | |
        2. 4.5.3.2 India | | |
        3. 4.5.3.3 Japan | | |
        4. 4.5.3.4 South Korea | | |
        5. 4.5.3.5 Malaysia | | |
        6. 4.5.3.6 Thailand | | |
        7. 4.5.3.7 Indonesia | | |
        8. 4.5.3.8 Rest of APAC | |
      4. 4.5.4 South America | | |
        1. 4.5.4.1 Brazil | | |
        2. 4.5.4.2 Mexico | | |
        3. 4.5.4.3 Argentina | | |
        4. 4.5.4.4 Rest of South America | |
      5. 4.5.5 MEA | | |
        1. 4.5.5.1 GCC Countries | | |
        2. 4.5.5.2 South Africa | | |
        3. 4.5.5.3 Rest of MEA 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Healthcare | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Cardinal Health (US) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 GE Healthcare (GB) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Bayer AG (DE) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 Novartis AG (CH) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 Siemens Healthineers (DE) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 Elekta AB (SE) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 Lantheus Medical Imaging (US) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 Bracco Imaging S.p.A. (IT) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies | |
      9. 5.2.9 NorthStar Medical Radioisotopes, LLC (US) | | |
        1. 5.2.9.1 Financial Overview | | |
        2. 5.2.9.2 Products Offered | | |
        3. 5.2.9.3 Key Developments | | |
        4. 5.2.9.4 SWOT Analysis | | |
        5. 5.2.9.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 NORTH AMERICA MARKET ANALYSIS |
    6. 6.3 US MARKET ANALYSIS BY APPLICATION |
    7. 6.4 US MARKET ANALYSIS BY TYPE |
    8. 6.5 US MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS |
    9. 6.6 US MARKET ANALYSIS BY END USE |
    10. 6.7 CANADA MARKET ANALYSIS BY APPLICATION |
    11. 6.8 CANADA MARKET ANALYSIS BY TYPE |
    12. 6.9 CANADA MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS |
    13. 6.10 CANADA MARKET ANALYSIS BY END USE |
    14. 6.11 EUROPE MARKET ANALYSIS |
    15. 6.12 GERMANY MARKET ANALYSIS BY APPLICATION |
    16. 6.13 GERMANY MARKET ANALYSIS BY TYPE |
    17. 6.14 GERMANY MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS |
    18. 6.15 GERMANY MARKET ANALYSIS BY END USE |
    19. 6.16 UK MARKET ANALYSIS BY APPLICATION |
    20. 6.17 UK MARKET ANALYSIS BY TYPE |
    21. 6.18 UK MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS |
    22. 6.19 UK MARKET ANALYSIS BY END USE |
    23. 6.20 FRANCE MARKET ANALYSIS BY APPLICATION |
    24. 6.21 FRANCE MARKET ANALYSIS BY TYPE |
    25. 6.22 FRANCE MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS |
    26. 6.23 FRANCE MARKET ANALYSIS BY END USE |
    27. 6.24 RUSSIA MARKET ANALYSIS BY APPLICATION |
    28. 6.25 RUSSIA MARKET ANALYSIS BY TYPE |
    29. 6.26 RUSSIA MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS |
    30. 6.27 RUSSIA MARKET ANALYSIS BY END USE |
    31. 6.28 ITALY MARKET ANALYSIS BY APPLICATION |
    32. 6.29 ITALY MARKET ANALYSIS BY TYPE |
    33. 6.30 ITALY MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS |
    34. 6.31 ITALY MARKET ANALYSIS BY END USE |
    35. 6.32 SPAIN MARKET ANALYSIS BY APPLICATION |
    36. 6.33 SPAIN MARKET ANALYSIS BY TYPE |
    37. 6.34 SPAIN MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS |
    38. 6.35 SPAIN MARKET ANALYSIS BY END USE |
    39. 6.36 REST OF EUROPE MARKET ANALYSIS BY APPLICATION |
    40. 6.37 REST OF EUROPE MARKET ANALYSIS BY TYPE |
    41. 6.38 REST OF EUROPE MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS |
    42. 6.39 REST OF EUROPE MARKET ANALYSIS BY END USE |
    43. 6.40 APAC MARKET ANALYSIS |
    44. 6.41 CHINA MARKET ANALYSIS BY APPLICATION |
    45. 6.42 CHINA MARKET ANALYSIS BY TYPE |
    46. 6.43 CHINA MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS |
    47. 6.44 CHINA MARKET ANALYSIS BY END USE |
    48. 6.45 INDIA MARKET ANALYSIS BY APPLICATION |
    49. 6.46 INDIA MARKET ANALYSIS BY TYPE |
    50. 6.47 INDIA MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS |
    51. 6.48 INDIA MARKET ANALYSIS BY END USE |
    52. 6.49 JAPAN MARKET ANALYSIS BY APPLICATION |
    53. 6.50 JAPAN MARKET ANALYSIS BY TYPE |
    54. 6.51 JAPAN MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS |
    55. 6.52 JAPAN MARKET ANALYSIS BY END USE |
    56. 6.53 SOUTH KOREA MARKET ANALYSIS BY APPLICATION |
    57. 6.54 SOUTH KOREA MARKET ANALYSIS BY TYPE |
    58. 6.55 SOUTH KOREA MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS |
    59. 6.56 SOUTH KOREA MARKET ANALYSIS BY END USE |
    60. 6.57 MALAYSIA MARKET ANALYSIS BY APPLICATION |
    61. 6.58 MALAYSIA MARKET ANALYSIS BY TYPE |
    62. 6.59 MALAYSIA MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS |
    63. 6.60 MALAYSIA MARKET ANALYSIS BY END USE |
    64. 6.61 THAILAND MARKET ANALYSIS BY APPLICATION |
    65. 6.62 THAILAND MARKET ANALYSIS BY TYPE |
    66. 6.63 THAILAND MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS |
    67. 6.64 THAILAND MARKET ANALYSIS BY END USE |
    68. 6.65 INDONESIA MARKET ANALYSIS BY APPLICATION |
    69. 6.66 INDONESIA MARKET ANALYSIS BY TYPE |
    70. 6.67 INDONESIA MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS |
    71. 6.68 INDONESIA MARKET ANALYSIS BY END USE |
    72. 6.69 REST OF APAC MARKET ANALYSIS BY APPLICATION |
    73. 6.70 REST OF APAC MARKET ANALYSIS BY TYPE |
    74. 6.71 REST OF APAC MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS |
    75. 6.72 REST OF APAC MARKET ANALYSIS BY END USE |
    76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
    77. 6.74 BRAZIL MARKET ANALYSIS BY APPLICATION |
    78. 6.75 BRAZIL MARKET ANALYSIS BY TYPE |
    79. 6.76 BRAZIL MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS |
    80. 6.77 BRAZIL MARKET ANALYSIS BY END USE |
    81. 6.78 MEXICO MARKET ANALYSIS BY APPLICATION |
    82. 6.79 MEXICO MARKET ANALYSIS BY TYPE |
    83. 6.80 MEXICO MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS |
    84. 6.81 MEXICO MARKET ANALYSIS BY END USE |
    85. 6.82 ARGENTINA MARKET ANALYSIS BY APPLICATION |
    86. 6.83 ARGENTINA MARKET ANALYSIS BY TYPE |
    87. 6.84 ARGENTINA MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS |
    88. 6.85 ARGENTINA MARKET ANALYSIS BY END USE |
    89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION |
    90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE |
    91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS |
    92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USE |
    93. 6.90 MEA MARKET ANALYSIS |
    94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION |
    95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY TYPE |
    96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS |
    97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY END USE |
    98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION |
    99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY TYPE |
    100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS |
    101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY END USE |
    102. 6.99 REST OF MEA MARKET ANALYSIS BY APPLICATION |
    103. 6.100 REST OF MEA MARKET ANALYSIS BY TYPE |
    104. 6.101 REST OF MEA MARKET ANALYSIS BY RADIOPHARMACEUTICAL CLASS |
    105. 6.102 REST OF MEA MARKET ANALYSIS BY END USE |
    106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
    107. 6.104 RESEARCH PROCESS OF MRFR |
    108. 6.105 DRO ANALYSIS OF HEALTHCARE |
    109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
    110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
    111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
    112. 6.109 HEALTHCARE, BY APPLICATION, 2024 (% SHARE) |
    113. 6.110 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion) |
    114. 6.111 HEALTHCARE, BY TYPE, 2024 (% SHARE) |
    115. 6.112 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion) |
    116. 6.113 HEALTHCARE, BY RADIOPHARMACEUTICAL CLASS, 2024 (% SHARE) |
    117. 6.114 HEALTHCARE, BY RADIOPHARMACEUTICAL CLASS, 2024 TO 2035 (USD Billion) |
    118. 6.115 HEALTHCARE, BY END USE, 2024 (% SHARE) |
    119. 6.116 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion) |
    120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    121. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.2.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.2.3 BY RADIOPHARMACEUTICAL CLASS, 2025-2035 (USD Billion) | |
      4. 7.2.4 BY END USE, 2025-2035 (USD Billion) |
    123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.3.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.3.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.3.3 BY RADIOPHARMACEUTICAL CLASS, 2025-2035 (USD Billion) | |
      4. 7.3.4 BY END USE, 2025-2035 (USD Billion) |
    124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.4.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.4.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.4.3 BY RADIOPHARMACEUTICAL CLASS, 2025-2035 (USD Billion) | |
      4. 7.4.4 BY END USE, 2025-2035 (USD Billion) |
    125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.5.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.5.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.5.3 BY RADIOPHARMACEUTICAL CLASS, 2025-2035 (USD Billion) | |
      4. 7.5.4 BY END USE, 2025-2035 (USD Billion) |
    126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.6.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.6.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.6.3 BY RADIOPHARMACEUTICAL CLASS, 2025-2035 (USD Billion) | |
      4. 7.6.4 BY END USE, 2025-2035 (USD Billion) |
    127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.7.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.7.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.7.3 BY RADIOPHARMACEUTICAL CLASS, 2025-2035 (USD Billion) | |
      4. 7.7.4 BY END USE, 2025-2035 (USD Billion) |
    128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.8.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.8.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.8.3 BY RADIOPHARMACEUTICAL CLASS, 2025-2035 (USD Billion) | |
      4. 7.8.4 BY END USE, 2025-2035 (USD Billion) |
    129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.9.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.9.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.9.3 BY RADIOPHARMACEUTICAL CLASS, 2025-2035 (USD Billion) | |
      4. 7.9.4 BY END USE, 2025-2035 (USD Billion) |
    130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.10.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.10.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.10.3 BY RADIOPHARMACEUTICAL CLASS, 2025-2035 (USD Billion) | |
      4. 7.10.4 BY END USE, 2025-2035 (USD Billion) |
    131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.11.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.11.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.11.3 BY RADIOPHARMACEUTICAL CLASS, 2025-2035 (USD Billion) | |
      4. 7.11.4 BY END USE, 2025-2035 (USD Billion) |
    132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.12.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.12.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.12.3 BY RADIOPHARMACEUTICAL CLASS, 2025-2035 (USD Billion) | |
      4. 7.12.4 BY END USE, 2025-2035 (USD Billion) |
    133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.13.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.13.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.13.3 BY RADIOPHARMACEUTICAL CLASS, 2025-2035 (USD Billion) | |
      4. 7.13.4 BY END USE, 2025-2035 (USD Billion) |
    134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.14.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.14.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.14.3 BY RADIOPHARMACEUTICAL CLASS, 2025-2035 (USD Billion) | |
      4. 7.14.4 BY END USE, 2025-2035 (USD Billion) |
    135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.15.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.15.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.15.3 BY RADIOPHARMACEUTICAL CLASS, 2025-2035 (USD Billion) | |
      4. 7.15.4 BY END USE, 2025-2035 (USD Billion) |
    136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.16.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.16.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.16.3 BY RADIOPHARMACEUTICAL CLASS, 2025-2035 (USD Billion) | |
      4. 7.16.4 BY END USE, 2025-2035 (USD Billion) |
    137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.17.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.17.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.17.3 BY RADIOPHARMACEUTICAL CLASS, 2025-2035 (USD Billion) | |
      4. 7.17.4 BY END USE, 2025-2035 (USD Billion) |
    138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.18.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.18.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.18.3 BY RADIOPHARMACEUTICAL CLASS, 2025-2035 (USD Billion) | |
      4. 7.18.4 BY END USE, 2025-2035 (USD Billion) |
    139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.19.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.19.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.19.3 BY RADIOPHARMACEUTICAL CLASS, 2025-2035 (USD Billion) | |
      4. 7.19.4 BY END USE, 2025-2035 (USD Billion) |
    140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.20.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.20.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.20.3 BY RADIOPHARMACEUTICAL CLASS, 2025-2035 (USD Billion) | |
      4. 7.20.4 BY END USE, 2025-2035 (USD Billion) |
    141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.21.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.21.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.21.3 BY RADIOPHARMACEUTICAL CLASS, 2025-2035 (USD Billion) | |
      4. 7.21.4 BY END USE, 2025-2035 (USD Billion) |
    142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.22.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.22.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.22.3 BY RADIOPHARMACEUTICAL CLASS, 2025-2035 (USD Billion) | |
      4. 7.22.4 BY END USE, 2025-2035 (USD Billion) |
    143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.23.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.23.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.23.3 BY RADIOPHARMACEUTICAL CLASS, 2025-2035 (USD Billion) | |
      4. 7.23.4 BY END USE, 2025-2035 (USD Billion) |
    144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.24.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.24.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.24.3 BY RADIOPHARMACEUTICAL CLASS, 2025-2035 (USD Billion) | |
      4. 7.24.4 BY END USE, 2025-2035 (USD Billion) |
    145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.25.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.25.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.25.3 BY RADIOPHARMACEUTICAL CLASS, 2025-2035 (USD Billion) | |
      4. 7.25.4 BY END USE, 2025-2035 (USD Billion) |
    146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.26.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.26.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.26.3 BY RADIOPHARMACEUTICAL CLASS, 2025-2035 (USD Billion) | |
      4. 7.26.4 BY END USE, 2025-2035 (USD Billion) |
    147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.27.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.27.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.27.3 BY RADIOPHARMACEUTICAL CLASS, 2025-2035 (USD Billion) | |
      4. 7.27.4 BY END USE, 2025-2035 (USD Billion) |
    148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.28.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.28.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.28.3 BY RADIOPHARMACEUTICAL CLASS, 2025-2035 (USD Billion) | |
      4. 7.28.4 BY END USE, 2025-2035 (USD Billion) |
    149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.29.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.29.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.29.3 BY RADIOPHARMACEUTICAL CLASS, 2025-2035 (USD Billion) | |
      4. 7.29.4 BY END USE, 2025-2035 (USD Billion) |
    150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.30.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.30.2 BY TYPE, 2025-2035 (USD Billion) | |
      3. 7.30.3 BY RADIOPHARMACEUTICAL CLASS, 2025-2035 (USD Billion) | |
      4. 7.30.4 BY END USE, 2025-2035 (USD Billion) |
    151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.31.1 |
    152. 7.32 ACQUISITION/PARTNERSHIP | |

Healthcare Market Segmentation

Healthcare By Application (USD Billion, 2025-2035)

  • Diagnosis
  • Therapy
  • Research

Healthcare By Type (USD Billion, 2025-2035)

  • Diagnostic Radiopharmaceuticals
  • Therapeutic Radiopharmaceuticals

Healthcare By Radiopharmaceutical Class (USD Billion, 2025-2035)

  • Radioisotopes
  • Radiolabeled Compounds
  • Radiopharmaceutical Generators

Healthcare By End Use (USD Billion, 2025-2035)

  • Hospitals
  • Diagnostic Imaging Centers
  • Research Institutions

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions